✦ LIBER ✦

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial

✍ Scribed by Poveda, A.; Vergote, I.; Tjulandin, S.; Kong, B.; Roy, M.; Chan, S.; Filipczyk-Cisarz, E.; Hagberg, H.; Kaye, S. B.; Colombo, N.; Lebedinsky, C.; Parekh, T.; Gomez, J.; Park, Y. C.; Alfaro, V.; Monk, B. J.

Book ID: 124100543
Publisher: Oxford University Press
Year: 2011
Tongue: English
Weight: 536 KB
Volume: 22
Category: Article
ISSN: 0923-7534
DOI: 10.1093/annonc/mdq352

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Trabectedin plus pegylated liposomal dox

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial

✍ Poveda, A.; Vergote, I.; Tjulandin, S.; Kong, B.; Roy, M.; Chan, S.; Filipczyk-C 📂 Article 📅 2011 🏛 Oxford University Press 🌐 English ⚖ 536 KB

8029 POSTER Health-Related Quality of Li

8029 POSTER Health-Related Quality of Life (HRQoL)/Patient Reported Outcomes (PRO) of Patients (pts) With Partially Platinum Sensitive (PPS) Recurrent Ovarian Cancer (ROC) Treated in a Randomized Phase III Trial of Trabectedin and Pegylated Liposomal Doxorubicin (PLD) Vs PLD Alone (OVA-301) – an Exploratory Analysis

✍ Verqote, I.; Bidzinski, M.; Kelley, J.; Vasanthan, S.; Runnebaum, I.; Vermorken, 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 45 KB